X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Ipsen acquires Epizyme’s lead medicine, Tazverik® (tazemetostat), a first-inclass, chemotherapy-free EZH2a inhibitor, which was granted Accelerated Approval by the U.S. Food and Drug Administration (FDA) in 2020.
Lead Product(s): Tazemetostat
Therapeutic Area: Oncology Product Name: Tazverik
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ipsen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 12, 2022
Details:
The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2[1] inhibitor, which was granted Accelerated Approval by the U.S. Food and Drug Administration (FDA) in 2020.
Lead Product(s): Tazemetostat
Therapeutic Area: Oncology Product Name: Tazverik
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ipsen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 27, 2022
Details:
Treatment with Tazverik (tazemetostat) and R2 was generally well tolerated and the adverse events were consistent with those contained in the prescribing information for both tazemetostat and R2, respectively.
Lead Product(s): Tazemetostat,Rituximab,Lenalidomide
Therapeutic Area: Oncology Product Name: Tazverik
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
TAZVERIK (tazemetostat), is a methyltransferase inhibitor of EZH21 is approved by the FDA for the treatment of certain patients with ES and certain patients with FL.
Lead Product(s): Tazemetostat
Therapeutic Area: Oncology Product Name: Tazverik
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Hutchmed
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
TST001 is a high affinity humanized anti-Claudin18.2 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities and potent anti-tumor activities in tumor xenograft models.
Lead Product(s): TST001,Capecitabine,Oxaliplatin
Therapeutic Area: Oncology Product Name: TST001
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Transcenta Holding
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
First patient dosed in the randomized portion of symphony-1 (EZH-302), epizyme’s phase 1B/3 confirmatory study of Tazverik (tazemetostat) in combination with rituximab + lenalidomide (R2) for the treatment of follicular lymphoma.
Lead Product(s): Tazemetostat,Lenalidomide,Rituximab
Therapeutic Area: Oncology Product Name: Tazverik
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2022
Details:
Epizyme anticipates using the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to fund global development and commercialization costs of tazemetostat outside of Japan.
Lead Product(s): Tazemetostat,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Tazverik
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $85.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 27, 2022
Details:
Among the 13 patients evaluated in this standard dose escalation design, no Dose Limiting Toxicities (DLTs) were observed during the first cycle of treatment up to the highest dose of 800mg of TAZVERIK twice daily.
Lead Product(s): Tazemetostat
Therapeutic Area: Oncology Product Name: Tazverik
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2021
Details:
The expanded loan facility is a part of the original loan agreement where Epizyme drew down $70 million to fund the regulatory milestones owed to Eisai for the New Drug Application submissions and U.S. FDA approvals of TAZVERIK® for epithelioid sarcoma and follicular lymphoma.
Lead Product(s): Tazemetostat
Therapeutic Area: Oncology Product Name: Tazverik
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pharmakon Advisors
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing November 06, 2020
Details:
Data supported the accelerated approval of TAZVERIK by the U.S. FDA for the treatment of epithelioid sarcoma in January 2020, and the accelerated approval of TAZVERIK by the FDA for the treatment of relapsed/refractory follicular lymphoma in June 2020.
Lead Product(s): Tazemetostat
Therapeutic Area: Oncology Product Name: Tazverik
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
